The
global anti-obesity
drugs market is growing significantly, due to high
prevalence of obesity and rich pipeline for anti-obesity drugs. The presence of
large patient pool and massive unexplored market in the emerging economies,
such as India and China, are creating ample opportunities for the growth of the
global anti-obesity drugs market. The advanced research and development
facilities, and new drug developments by the key players are propelling the
demand for improved and cost-effective anti-obesity drugs, thus driving the
growth of the global anti-obesity drugs market.
Obesity
can be defined as a medical condition, in which excessive or abnormal
accumulation of fat occurs in a patient. A person with body mass index (BMI) of
30 or above is considered obese. There are several factors causing obesity,
such as eating habits, physical inactivity, and genetic makeup. Obesity has
serious negative impact on an individual’s health. An obese individual is at a
higher risk of developing chronic diseases, such as breast cancer, endometrial
cancer, colon cancer, type 2 diabetes, cardiovascular diseases, and
musculoskeletal disorders. According to the WHO, in 2014, there were 600
million obese people aged 18 years or above, which accounted for 13% of the
total adult population in the world. The prevalence of obesity is the highest
in the U.S. According to the Center for Disease Control and Prevention (CDC),
in the U.S., 35.1% of the adult population aged 20 years or above were obese
during 2011 - 2012.
Request to
Get the Sample Pages at:
Geographically,
North America leads the global anti-obesity drugs market, due to high
incidences of obesity, high healthcare expenditure, and increased awareness
about obesity and obesity related risks among patients. In addition, the
increasing involvement of government and non-government organizations to
educate and aware people about the ill effects of obesity, and extensive
research and development activities for the development of anti-obesity drugs
are fueling the growth of the anti-obesity drugs market in North America.
Asia-Pacific is the fastest growing region in the global anti-obesity drugs
market. The fastest growth of the region is attributed to improving healthcare
infrastructure, growing healthcare expenditure and increasing geriatric
population. Moreover, the anti-obesity drugs market is growing due to increasing
research and development facilities, growing disposable income, and presence of
large patient pool in the emerging countries, such as India and China.
Some of the major
players operating in the global anti-obesity drugs market are F. Hoffmann-La
Roche AG, Arena Pharmaceuticals Inc., Orexigen Therapeutics Inc.,
GlaxoSmithKline PLC, Boehringer Ingelheim GmbH, Pfizer Inc., Merck & Co.
Inc., Takeda Pharmaceuticals Company Limited, Eisai Co. Ltd., Novo Nordisk A/S,
Zafgen, Rhythm Pharmaceuticals, Zydus Cadila, and Norgine B.V.
